For Our Patients
Clinical Trials and Research
All Upcoming
Studies
Clinical trials are designed to test the safety and efficacy of new approaches to preventing, detecting, and treating disease. Research and clinical trials also continuously look for new ways to use existing treatments, new drugs, surgical procedures and devices.
Florida Retina Institute clinical trial participants may enroll to possibly receive the newest treatment for their vitreoretinal conditions, as well as to have additional care and attention from clinical trial staff and with the results and outcome of their trial, help researchers find better treatments for future patients.
Detailed information about all Upcoming Studies
For Central Florida Patients
Magic: Diabetic Non-Persusion
Faricimab for retinal non-perfusion associated with non-proliferative diabetic retinopathy: The MAGIC Phase 2, multi-center, open-label, randomized controlled trial.
Qauser: Retinal Vein Oclusions
Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. [IND # 12462 (Regeneron Pharmaceuticals, Inc.)]
For North Florida Patients
ADVM-022-11 – LUNA Neovascular (Wet) Age-Related Macular Degeneration
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
OcuTerra Therapeutics, Inc.- DREAM (NPDR/PDR)
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
BP44241 For CRVO - F. Hoffmann-La Roche
A PHASE Ib, multicenter, randomized, double masked, active comparator-controlled study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200394 in participants with macular edema secondary to central retinal vein occlusion.
The Magic Study for NPDR
Faricimab for retinal non-perfusion associated with non-proliferative Diabetic Retinopathy: The Magic Phase 2, multi-center, open-label, randomized, controlled trial.
F. Hoffmann-La Roche- Diabetic Macular Edema
A Phase II, Multicenter, Randomized, Double Masked, Active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.
SHANGHAI HENLIUS FOR WET AMD
A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).
ONL Therapeutics, Inc. (Retinal Detachment)
Protocol: ONL1204-RRD-002
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 in Subjects with Macula-off Rhegmatogenous Detachment.
Upcoming in 2024 COGNITION Therapeutics (Dry AMD)
Protocol: COG2201 A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
If you want to see a list of clinical trials, please click here and go to Clinicaltrials.gov, a resource provided by the U.S. National Library of Medicine. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.
